EGFR is a protein found at high levels in many types of cancers, particularly non-small cell lung cancer (NSCLC). Activating mutations in the EGFR gene are present in a proportion of NSCLC tumours. Tumours with mutated EGFR show a higher likelihood of response to treatment with EGFR tyrosine kinase inhibitor drugs e.g. Iressa (Gefitinib).
Please refer to the National Genomic Test Directory for Cancer here.
Targeted EGFR (Salvage pathway) 7 calendar days
T790M targeted test 7 calendar days
NSCLC panel 14 calendar days
Please refer to our Sample Requirements section before sending any samples to us for testing.